Masaoki Sasaki

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

Kenji Tamura, Hirofumi Mukai, Yoichi Naito et al. · Cancer Science · 2016 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

A first-in-human Phase 1 study of epirubicin-conjugated polymer micelles (K-912/NC-6300) in patients with advanced or recurrent solid tumors

Hirofumi Mukai, Takahiro Kogawa, Nobuaki Matsubara et al. · Investigational New Drugs · 2017 · 82 citations

Medicine, Oncology, Pharmacology +16

Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR

Nobuaki Matsubara, Hirofumi Mukai, Mariko Masumoto et al. · Breast Cancer Research and Treatment · 2014 · 40 citations

Medicine, Oncology, Breast Oncology +16

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer

Nobuaki Matsubara, Hirofumi Mukai, Ako Hosono et al. · Cancer Chemotherapy and Pharmacology · 2017 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status

Maki Tanioka, Masaoki Sasaki, Akihiko Shimomura et al. · The Breast · 2014 · 28 citations · Full text

Medicine, Oncology, Breast Oncology +16